Feiran Lou to Lung Neoplasms
This is a "connection" page, showing publications Feiran Lou has written about Lung Neoplasms.
Connection Strength
1.900
-
Reddington H, Ballinger Z, Guart J, Emmerick I, Crawford A, Maxfield M, Uy K, Lou F. National adoption of robotic-assisted thoracoscopic surgery for oncologic lung resections. J Robot Surg. 2025 Sep 04; 19(1):557.
Score: 0.608
-
Lou F, Sima CS, Rusch VW, Jones DR, Huang J. Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung?cancer. Ann Thorac Surg. 2014 Nov; 98(5):1755-60; discussion 1760-1.
Score: 0.282
-
Lou F, Sarkaria I, Pietanza C, Travis W, Roh MS, Sica G, Healy D, Rusch V, Huang J. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013 Oct; 96(4):1156-1162.
Score: 0.263
-
DeFazio MW, Selove W, Watts G, Harchandani S, Sood R, Lou F, Most MJ. Recurrent Giant Cell Tumor of Bone with New Pulmonary Metastases 9 Years After En Bloc Distal Radius Resection: A Case Report. JBJS Case Connect. 2023 07 01; 13(3).
Score: 0.131
-
Bai S, Millis M, Wilson S, Scott M, Goulart RA, Maxfield MW, Lou F, Sood RN, Fischer AH. Liquid-based rapid onsite evaluation of endobronchial ultrasound cytologies. J Am Soc Cytopathol. 2022 Nov-Dec; 11(6):375-384.
Score: 0.122
-
Emmerick ICM, Singh A, Powers M, Lou F, Lin P, Maxfield M, Uy K. Factors associated with diagnosis of stages I and II lung cancer: a multivariate analysis. Rev Saude Publica. 2021; 55:112.
Score: 0.117
-
Emmerick ICM, Uy K, Guiab K, Powers M, Lou F, Lin P, Maxfield M, Voland R, Varlotto J. Impact of the National Lung Screening Trial (NLST) publication and Medicare Lung cancer screening payment on lung cancer incidence rates: An interrupted time series analysis. J Cancer Policy. 2022 03; 31:100318.
Score: 0.117
-
Ripley RT, McMillan RR, Sima CS, Hasan SM, Ahmad U, Lou F, Jones DR, Rusch VW, Rizk NP, Huang J. Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg. 2014 Sep; 98(3):968-74.
Score: 0.070
-
Farjah F, Lou F, Sima C, Rusch VW, Rizk NP. A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. J Thorac Oncol. 2013 Sep; 8(9):1170-80.
Score: 0.066
-
Amini A, Lou F, Correa AM, Baldassarre R, Rimner A, Huang J, Roth JA, Swisher SG, Vaporciyan AA, Lin SH. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann Surg Oncol. 2013 Jun; 20(6):1934-40.
Score: 0.063
-
Farjah F, Lou F, Rusch VW, Rizk NP. The quality metric prolonged length of stay misses clinically important adverse events. Ann Thorac Surg. 2012 Sep; 94(3):881-7; discussion 887-8.
Score: 0.061